Overview

A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Status:
Recruiting
Trial end date:
2026-02-20
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Salubris Biotherapeutics Inc